6/13
01:39 pm
trvi
Rating for TRVI
Low
Report
Rating for TRVI
6/13
07:38 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $7.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $7.00 price target on the stock.
6/13
07:38 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $7.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $7.00 price target on the stock.
6/12
05:26 pm
trvi
Trevi Therapeutics initiated with bullish view at Rodman & Renshaw
Medium
Report
Trevi Therapeutics initiated with bullish view at Rodman & Renshaw
6/12
05:26 pm
trvi
Trevi Therapeutics initiated with bullish view at Rodman & Renshaw
Medium
Report
Trevi Therapeutics initiated with bullish view at Rodman & Renshaw
5/8
10:09 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
5/8
09:25 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
5/8
09:25 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
4/9
08:09 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
4/9
06:04 am
trvi
Rating for TRVI
Medium
Report
Rating for TRVI
4/9
06:04 am
trvi
Rating for TRVI
Medium
Report
Rating for TRVI
3/21
09:37 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
3/21
08:49 am
trvi
Rating for TRVI
High
Report
Rating for TRVI
3/21
08:49 am
trvi
Rating for TRVI
High
Report
Rating for TRVI
3/21
08:06 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
3/21
06:46 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
3/21
06:46 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI